| Trial ID: | L5233 |
| Source ID: | NCT00491543
|
| Associated Drug: |
Alt-2074
|
| Title: |
Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Coronary Artery Disease
|
| Interventions: |
DRUG: ALT-2074
|
| Outcome Measures: |
Primary: Biomarkers of inflammation and oxidative stress, 28 days|Safety, 28 days|Pharmacokinetics, 28 days |
|
| Sponsor/Collaborators: |
Sponsor: Synvista Therapeutics, Inc
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-06
|
| Completion Date: |
2008-05
|
| Results First Posted: |
|
| Last Update Posted: |
2008-07-02
|
| Locations: |
Radiant Research, Chicago, Illinois, 60610, United States|Radiant Research, Cincinnati, Ohio, 45249, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00491543
|
